INSM: the cashflow

MyFinsight

For the year ending 2025-12-31, INSM had -$44,585K decrease in cash & cash equivalents over the period. -$967,575K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-12-31
Net loss	-1,276,775
Depreciation	10,449
Amortization of intangible assets	6,001
Stock-based compensation expense	152,710
Amortization of debt issuance costs	6,216
Paid-in-kind interest capitalized	0
Royalty financing non-cash interest expense	20,675
Accretion of discount on marketable securities, net	38,348
Finance lease amortization expense	2,712
Non-cash operating lease expense	9,652
Change in fair value of deferred and contingent consideration liabilities	251,993
Change in fair value of interest rate swap	0
Vertuis/adrestia acquisition-Vertuis Bio Inc	0
Vertuis/adrestia acquisition-Adrestia Therapeutics Ltd	0
Accounts receivable	88,307
Inventory	31,519
Prepaid expenses and other current assets	53,431
Other assets	2,123
Accounts payable and accrued liabilities	100,073
Other liabilities	-4,992
Net cash used in operating activities	-935,014
Purchase of fixed assets	32,561
Payment of az milestone	30,000
Purchase of marketable securities	2,092,014
Cash acquired in asset acquisition	0
Maturities of marketable securities	2,090,000
Net cash used in investing activities	-64,575
Proceeds from exercise of stock options and espp	135,717
Proceeds from issuance of common stock, net	823,282
Proceeds from issuance of term loan	0
Payments of principal of 0.75 convertible senior notes due 2028	1,965
Payment of debt issuance costs	0
Payments of finance lease principal	2,961
Net cash provided by financing activities	954,073
Effect of exchange rates on cash and cash equivalents	931
Net (decrease) increase in cash and cash equivalents	-44,585

Unit: Thousand (K) dollars